Dexter L.

EviGeno is an independent patient advocacy and medical intelligence practice I founded to close the information gap in rare, genetic, and advanced disease. Patient Advocacy & Medical Navigation: Working directly with patients and families as an independent advocate — taking case details, genomic/NGS reports, and clinical history to map globally available trials, off-label options, and emerging therapies against their specific molecular profile. Services include second opinion facilitation, clinical trial matching, and therapy navigation for oncology and rare disease cases where standard care has reached its limits. Biopharma CI & China Market Intelligence: Working with life sciences executives on China-side competitive intelligence, clinical trial tracking, and pipeline research — translating fragmented data from NMPA, CDE, ChiCTR, and local sources into actionable intelligence.

Partner with the CEO on OKRs across AI infrastructure and IND application workflows. Run global biopharma market intelligence and lead generation: identifying high-value target accounts (Biotech/CRO/CDMO), surfacing their needs, verifying contact data, and drafting outreach. Support FDA regulatory documentation and IND submission preparation using AI-assisted writing and compliance review workflows. Curate industry insight at the intersection of AI and drug development.

Managed corporate governance and zero-error documentation for an SSE STAR Market IPO preparation — building hands-on expertise in Chinese regulatory filings, public-record verification, and cross-functional compliance workflows. Developed deep familiarity with Chinese corporate data infrastructure, funding structures, and executive verification — directly transferable to the due diligence and competitive intelligence work I now deliver for international clients. less

Responsible for technical promotion of Olympus GI endoscopy products across North China — bridging clinical application and commercial positioning for hospital and distributor audiences. Translated complex clinical value propositions into training materials and academic workshop content for healthcare professionals, requiring both medical accuracy and practical clarity. This role built my foundational fluency in medical device commercialization, clinical communication, and the hospital procurement environment in China.

Interpreted NGS (Next-Generation Sequencing) reports for oncology patients, translating raw sequencing data into actionable clinical recommendations for treating physicians. Served as primary technical consultant for cancer gene panels — cross-referencing patient molecular profiles against FDA and NMPA approved targeted therapies to support treatment decision-making. This role is the foundation of everything I do now: reading a genomic profile and understanding what it actually means clinically, commercially, and for the patient.